Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 2/20 | 0.57 |
| ▸ | NAPEPLD | Q6IQ20 | 4/20 | 0.52 |
| ▸ | THRB | P10828 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24766039 | 0.86 | MAPT (0.47) | PIK3CBNAPEPLDTHRBMAPTKMT2A | |
| SCHEMBL24766030 | 0.85 | KMT2A (0.47) | PIK3CBTHRBMAPTKMT2ACYP1A2 | |
| SCHEMBL244072 | 0.84 | PIK3CA (0.47) | PIK3CBTHRBMAPTKMT2ACYP1A2 | |
| SCHEMBL29434078 | 0.84 | PIK3CA (0.47) | PIK3CBTHRBMAPTKMT2ACYP1A2 | |
| SCHEMBL242170 | 0.83 | KMO (0.56) | PIK3CBTHRBMAPTKMT2ACYP1A2 | |
| SCHEMBL29434113 | 0.80 | SMN1; SMN2 (0.43) | PIK3CBNAPEPLDMAPTKMT2AMEN1 | |
| SCHEMBL24766834 | 0.80 | SMN1; SMN2 (0.43) | PIK3CBNAPEPLDMAPTKMT2AMEN1 | |
| SCHEMBL29434180 | 0.78 | GSK3B (0.47) | PIK3CBTHRBMAPTKMT2ACYP1A2 | |
| SCHEMBL243488 | 0.78 | PIK3CB (0.48) | PIK3CBNAPEPLDMAPTKMT2ACYP1A2 | |
| SCHEMBL17204101 | 0.77 | MAPT (0.61) | PIK3CBMAPTKMT2ACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2588473-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| WO-2012003264-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003264-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CB 44/4885NAPEPLD 127/4885THRB 2477/4885 |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CB 40/4885NAPEPLD 139/4885THRB 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.